Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.43 |
| ▸ | PPARD | Q03181 | 8/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16886207 | 0.93 | PTGDR2 (0.35) | PTGDR2PPARDPTGS1PTGS2NPC1 | |
| SCHEMBL4567006 | 0.91 | PPARD (0.36) | PTGDR2PPARD | |
| SCHEMBL202352 | 0.89 | PPARD (0.46) | PPARD | |
| SCHEMBL19471067 | 0.89 | PPARD (0.44) | PPARD | |
| SCHEMBL202599 | 0.88 | SCN9A (0.40) | PTGDR2PPARDFFAR4SCN9ANPC1 | |
| SCHEMBL2704979 | 0.88 | PTGDR2 (0.33) | PTGDR2PPARDPTGS1PTGS2NPC1 | |
| SCHEMBL19471085 | 0.88 | PPARD (0.45) | PTGDR2PPARDFFAR4 | |
| SCHEMBL19471066 | 0.88 | PPARD (0.44) | PPARD | |
| SCHEMBL2706591 | 0.84 | PPARD (0.39) | PPARDSCN9A | |
| SCHEMBL201115 | 0.82 | PPARD (0.44) | PTGDR2PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305943-A1 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | TAXIS PHARMACEUTICALS, INC. (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170305943-A1 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | TAXIS PHARMACEUTICALS, INC. (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170305943-A1 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | TAXIS PHARMACEUTICALS, INC. (US) | 2017-10-26 | — | — | US | disclosed |
| US-20150191420-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. | 2015-07-09 | — | — | US | disclosed |
| US-20150191420-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. | 2015-07-09 | — | — | US | disclosed |
| US-20150191420-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. | 2015-07-09 | — | — | US | disclosed |
| US-8865736-B2 | Antibacterial agents | Biota Scientific Pty Ltd (AU) | 2014-10-21 | — | — | US | disclosed |
| US-8865736-B2 | Antibacterial agents | Biota Scientific Pty Ltd (AU) | 2014-10-21 | — | — | US | disclosed |
| US-8865736-B2 | Antibacterial agents | Biota Scientific Pty Ltd (AU) | 2014-10-21 | — | — | US | disclosed |
| US-20130072520-A2 | ANTIBACTERIAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-03-21 | — | — | US | disclosed |
| US-20130072520-A2 | ANTIBACTERIAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-03-21 | — | — | US | disclosed |
| US-20130072520-A2 | ANTIBACTERIAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-03-21 | — | — | US | disclosed |
| US-20120122918-A1 | ANTIBACTERIAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-05-17 | — | — | US | disclosed |
| US-8088791-B2 | Antibacterial agents | Biots Scientific Management Pty Ltd (AU) | 2012-01-03 | — | — | US | disclosed |
| EP-1996180-B1 | BENZAMIDE AND PYRIDYLAMIDE DERIVATIVES AS ANTIBACTERIAL AGENTS | BIOTA EUROPE LTD (GB) | 2011-08-03 | — | — | EP | disclosed |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2010-07-08 | — | — | US | disclosed |
| WO-2007107758-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122918-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, ARG1 | PTGDR2 2035/4885PPARD 3683/4885FFAR4 2271/4885 |
| US-20130072520-A2 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | PTGDR2 2116/4885PPARD 3689/4885FFAR4 2301/4885 |
| US-20150191420-A1 | ANTIBACTERIAL AGENTS | ALK, ARG1, ROS1 | PTGDR2 1789/4885PPARD 3598/4885FFAR4 2025/4885 |
| US-20170305943-A1 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | ELANE, MMP8, NISCH | PTGDR2 1177/4885PPARD 1754/4885FFAR4 3484/4885 |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | PTGDR2 2116/4885PPARD 3689/4885FFAR4 2301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.